IGDRASOL THERAPEUTICS
Focusing on the development of oncologic agents for the treatment for cancers
IGDRASOL THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Biotherapies
Biotherapies, Inc. is dedicated to the development of better cancer treatment and diagnosis.
Famous Biotech
focus on the development of anticancer small molecule
Fast BioPharma
Fast BioPharma Ltd. develops therapeutic products for treatment of cancer.
Hermes Biosciences
HERMES Biosciences, Inc. engages in the development of targeted drug delivery technologies for therapeutics.
Mabpharm Private Ltd
Mabpharm is engaged in development of monoclonal antibodies for treatment of cancer and auto-immune diseases.
Pharmagap Inc.
Pharmagap is a company that develops therapeutic drugs for the treatment of cancer.
ScandiBio Therapeutics
We develop metabolic co-factors that can be used in treatment of metabolic diseases.
Umut Biotechnology
Population and ethnicity specific genetic risk assessment test using DNA biomarkers for breast cancer.
WeMED Bio-Tech Inc.
Research and development of medical devices targeted at unmet needs
Founder
More informations about "Igdrasol Therapeutics"
Sorrento Therapeutics Completes IgDraSol Merger - PR Newswire
SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has completed the merger with IgDraSol, Inc., a privately …See details»
Sorrento Therapeutics Completes IgDraSol Merger
The acquisition of IgDraSol bolsters our leadership team with highly relevant and successful experience in developing and commercializing cancer therapeutics, including Abraxane ®. We …See details»
Igdrasol Therapeutics - Drug pipelines, Patents, Clinical trials
Last update 11 Jul 2024. Igdrasol Therapeutics. Private CompanySee details»
Sorrento Boosts Cancer Pipeline with Igdrasol Purchase
Mar 7, 2013 Deal includes formulation technology that the companies envision as a foundation for new targeted therapeutics. genprowebdirectory Facebook Linkedin RSS Twitter YoutubeSee details»
NantPharma to buy Sorrento’s Igdrasol - Pharmaceutical Technology
May 17, 2015 NantWorks ecosystem of companies member NantPharma has agreed to acquire a wholly owned subsidiary of Sorrento, Igdrasol, in a deal worth $1.3bn. The deal will allow …See details»
Sorrento Therapeutics, Inc. and IGDRASOL Announce the …
May 13, 2013 SAN DIEGO and IRVINE, Calif., May 13, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today the acquisition of …See details»
Sorrento Therapeutics signs exclusive option to acquire IGDRASOL
Mar 8, 2013 USA-based Sorrento Therapeutics, Inc. (SRNE: OB) has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for …See details»
Sorrento Therapeutics
Responsible for building Abraxis commercial organization George Uy CCO CCO of IgDraSol Directed the launches of Abraxane, Xeloda ® & Fusilev Built commercial infrastructures and …See details»
Sorrento Therapeutics, Inc. and IGDRASOL Will Present ... - ADVFN
Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia PR Newswire …See details»
Sorrento Therapeutics and IGDRASOL Proceed with Development …
3 days ago Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway Official Minutes from End-of-Phase 2 …See details»
Igdrasol Therapeutics - Crunchbase
Focusing on the development of oncologic agents for the treatment for cancersSee details»
Sorrento Therapeutics Completes IgDraSol Merger - ADVFN
Sorrento Therapeutics Completes IgDraSol Merger PR Newswire SAN DIEGO, Sept. 10, 2013 SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; …See details»
Igdrasol Therapeutics - Tech Stack, Apps, Patents & Trademarks
Focusing on the development of oncologic agents for the treatment for cancersSee details»
Sorrento, Igdrasol Secure Exclusive E.U. Distribution Rights to …
Sorrento Therapeutics and Igdrasol have acquired from Samyang Biopharmaceuticals exclusive E.U. distribution rights to Cynviloq™, a micellar paclitaxel formulation.See details»
EX-99.1 - SEC.gov
But it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics’ proprietary G-MAB ® fully-human …See details»
Sorrento Therapeutics, Inc. and IGDRASOL Present Phase I
May 28, 2013 SAN DIEGO and IRVINE, Calif., May 28, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCBB: SRNE; STI) and IGDRASOL announced today that clinical data …See details»
Sorrento Therapeutics, Inc. and IGDRASOL Announce Three …
Mar 31, 2013 SAN DIEGO and FOUNTAIN VALLEY, Calif., March 31, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today that IGDRASOL …See details»
Sorrento Therapeutics, Inc. and IGDRASOL present Phase I clinical …
May 28, 2013 SAN DIEGO and IRVINE, Calif., May 28, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCBB: SRNE; STI) and IGDRASOL announced today that clinical data …See details»